Fractyl Health, Inc. (GUTS)

In September 2025, positive REMAIN-1 Midpoint Cohort results led to a 35.6% stock increase. November 2025 saw a 2.73% stock rise after Q3 financial results despite a widened net loss. December 2025 had positive REVEAL-1 results, causing a 17.95% stock gain and a call of Tranche A Warrants. January 2026 included a CFO appointment and a 2026 roadmap announcement, resulting in stock declines of 2.91% and 8.44%, respectively.

While specific demand seasonality for Fractyl Health's products is not detailed, the broader metabolic disorder therapeutics market can experience seasonal variations. The company's focus on addressing the root causes of chronic conditions suggests a continuous underlying need for its solutions, potentially mitigating purely seasonal demand.

Fractyl Health, Inc. is a metabolic therapeutics company focused on developing innovative treatments for metabolic diseases like type 2 diabetes and obesity. Their lead product, the Revita DMR System, is an outpatient procedural therapy designed to modify duodenal dysfunction. Rejuva is a pancreatic gene therapy platform in preclinical development, aiming for long-term remission of T2D and obesity.

Fractyl Health is headquartered in Burlington, Massachusetts, USA. The Revita DMR System is commercially available in the UK since January 2020 and in Germany since early 2023. Clinical trials, including the REMAIN-1 pivotal study, are being conducted across the United States.

Fractyl Health's brand reputation has been largely positive due to promising clinical trial results and a focus on addressing unmet medical needs in metabolic diseases. Positive data from the REMAIN-1 and REVEAL-1 studies, along with FDA Breakthrough Device designation for Revita, have bolstered the company's credibility. The company's strategic focus on durable therapies for obesity and type 2 diabetes has also been well-received.

Approximately 55.86% to 66.76% of Fractyl Health's stock is held by institutional investors, 16.27% to 21.22% by insiders, and 12.02% to 24.58% by retail investors. Major institutional owners include Nantahala Capital Management, LLC, Silverarc Capital Management, LLC, Alyeska Investment Group, L.P., Woodline Partners LP, Catalio Capital Management, LP, Rosalind Advisors, Inc., General Catalyst Group Management, LLC and Mithril LP. CEO Harith Rajagopalan owns 0.8% of the company's shares.